Yes, they complement each other and don't compete.
If you look at the broker report on Recell, its full of inaccuracies and NICE rejected their economic model as unrealistic. The slow growth in sales of Recell might be a reflection of that, and I see many posters in the AVH thread attributing mythical properties and wanting to "redo" existing scars with it to remove them.
PNV though is on solid ground. Its probably already reached breakeven on a monthly basis and I am expecting continued steady growth which will likely be boosted by the CE approval. If that reults in sales in Europe and to the NHS, then its probably easily worth $1.50.
Maybe the share price is a little ahead of itself now, but thats a refection of investors not wanting to get left out.
PNV Media Thread, page-39
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.09 |
Change
0.080(3.98%) |
Mkt cap ! $1.442B | |||
| Open | High | Low | Value | Volume |
| $2.03 | $2.09 | $2.03 | $1.476M | 710.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5010 | $2.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.09 | 135016 | 10 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.09 |
Change
0.080 ( 3.33 %) |
||||
| Open | High | Low | Volume | ||
| $2.03 | $2.09 | $2.03 | 302647 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| PNV (ASX) Chart |